How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

220 results for

Dopamine Agonist in Hyperprolactinemia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history. (PubMed)

Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history. Hyperprolactinemia is the presence of abnormally high circulating levels of prolactin. Idopathic hyperprolactinemia is the term used when no cause of prolactin hypersecretion can be identified and it is causally related to the development of miscarriage in pregnant women, especially women who have a history of recurrent miscarriage. A possible mechanism is that high (...) levels of prolactin affect the function of the ovaries, resulting in a luteal phase defect and miscarriage. A dopamine agonist is a compound with high efficacy in lowering prolactin levels and restoring gonadal function.To assess the effectiveness and safety of different types of dopamine agonists in preventing future miscarriage given to women with idiopathic hyperprolactinemia and a history of recurrent miscarriage.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 June

Full Text available with Trip Pro

2016 Cochrane

2. Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. (PubMed)

Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. There are growing reports of dopamine agonist (DA)-induced impulse control disorders (ICDs) in hyperprolactinemic patients. However, the magnitude of this risk and predictive factors remain uncertain.To determine ICD prevalence and risk factors in DA-treated hyperprolactinemic patients compared to community controls.Multicenter cross-sectional analysis of 113 patients and 99 healthy

2019 Journal of Clinical Endocrinology and Metabolism

3. Psychological effects of Dopamine Agonist Treatment in Patients with Hyperprolactinemia and Prolactin Secreting Adenomas. (PubMed)

Psychological effects of Dopamine Agonist Treatment in Patients with Hyperprolactinemia and Prolactin Secreting Adenomas. Background Dopamine agonists (DAs) are the main treatment for patients with hyperprolactinemia and prolactinomas. Recently, an increasing number of reports emphasized DAs' psychological side effects, either de novo or as exacerbations of prior psychiatric disease. Methods Review of prospective and retrospective studies (PubMed 1976, September 2018) evaluating (...) the psychological profile of DA-treated patients with hyperprolactinemia and prolactinomas. Case series and case reports of psychiatric complications were also reviewed. Results Most studies were cross-sectional and had a control group of healthy volunteers or patients with nonfunctioning pituitary adenomas. There were few prospective studies, with/without control group, that included small numbers of patients. Compared with controls, patients with hyperprolactinemia generally had worse quality of life, anxiety

2018 European Journal of Endocrinology

4. Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03038308 Recruitment Status : Recruiting First Posted : January 31, 2017 Last Update

2017 Clinical Trials

5. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. (PubMed)

Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Dopamine agonists (DAs) are recommended as first-line treatment for patients with hyperprolactinemia. Generally, it is accepted that patients with hyperprolactinemia do not need lifelong medication, but the optimal timing for DA withdrawal has not been determined. The aim of this systematic review and meta-analysis is to assess the impact of DA withdrawal on the clinical (...) outcomes of patients with hyperprolactinemia, and to explore possible factors affecting successful DA withdrawal.The databases of PubMed, Cochrane and EMBASE were searched up to May 2016.The proportion of patients with persisting normoprolactinemia after DA withdrawal reached 36.6% in a random effects model (95% CI, 29.4-44.2%; I-squared: 82.5%). Data of stratified analysis showed that the success rate of drug withdrawal was high in patients using cabergoline (CAB) as the only treatment (41.2%; 95% CI

2017 Endocrine

6. Pulmonary Artery Occlusion and Mediastinal Fibrosis in a Patient on Dopamine Agonist Treatment for Hyperprolactinemia (PubMed)

Pulmonary Artery Occlusion and Mediastinal Fibrosis in a Patient on Dopamine Agonist Treatment for Hyperprolactinemia Unusual forms of pulmonary hypertension include pulmonary hypertension related to mediastinal fibrosis and the use of serotonergic drugs. Here, we describe a patient with diffuse mediastinal fibrosis and pulmonary hypertension while she was on dopamine agonist therapy. A young woman, who was treated with cabergoline and bromocriptine for hyperprolactinemia, presented (...) of the right pulmonary artery showed fibrosis and chronic inflammation. Subsequent investigations revealed that diffuse mediastinal fibrosis with concurrent pulmonary hypertension, and not CTEPH, was the most likely diagnosis and cabergoline and bromocriptine may have triggered the fibrotic changes. Both drugs are ergot-derived dopamine agonists, which are known to cause cardiac valve fibrosis and less frequently, non-cardiac fibrotic changes. The underlying mechanism is attributed to their interactions

Full Text available with Trip Pro

2017 Frontiers in pharmacology

7. Osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: A systematic review and meta-analysis. (PubMed)

Osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: A systematic review and meta-analysis. Hyperprolactinemia is associated with bone fragility. Traditionally attributed to prolactin-induced hypogonadism, recent studies have identified increased fracture rates independent of gonadal function.We performed a systematic review to identify studies assessing fracture risk in patients with untreated hyperprolactinemia compared to those on dopamine (...) %.In the limited studies available, fracture prevalence was increased in patients with untreated hyperprolactinemia compared to those on treatment, independent of gonadal function. Further studies are needed to clarify if post-menopausal women, or high-risk men, with no other indication for treatment, should be on dopamine agonists to decrease fracture risk.

2016 Neuro endocrinology letters

8. Dopamine Agonist in Hyperprolactinemia

Dopamine Agonist in Hyperprolactinemia Dopamine Agonist in Hyperprolactinemia Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Dopamine (...) Agonist in Hyperprolactinemia Dopamine Agonist in Hyperprolactinemia Aka: Dopamine Agonist in Hyperprolactinemia , Dopamine Agonist in Type 2 Diabetes Mellitus , Bromocriptine , Parlodel , Cabergoline , Dostinex , Bromocriptine QR , Cycloset From Related Chapters II. Indications III. Dosing: Hyperprolactinemia Bromocriptine (Parlodel) Larger safety database than Cabergoline (preferred in women trying to conceive) Start: 1.25 to 2.5 mg at bedtime Titrate: Increase by 2.5 mg every 3-7 days up to 15 mg

2018 FP Notebook

9. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis

Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

10. MANAGEMNT OF ENDOCRINE DISEASE: Impulse control disorders in patients with hyperpolactinemia treated with dopamine agonists: how much should we worry? (PubMed)

MANAGEMNT OF ENDOCRINE DISEASE: Impulse control disorders in patients with hyperpolactinemia treated with dopamine agonists: how much should we worry? Dopamine agonists (DAs) represent a cornerstone in the management of patients with hyperprolactinemia and have an important role in the treatment of neurologic disorders, including Parkinson's disease and restless legs syndrome. A growing body of evidence has identified impulse control disorders (ICDs) as possible adverse effects of DA therapy (...) . A variety of ICDs may occur in patients treated with DA, including compulsive shopping, pathologic gambling, stealing, hypersexuality and punding (repetitive performance of tasks, such as collecting, sorting, disassembling and assembling objects). These behaviors can have devastating effects on patients' life and family. In the present review article, we summarize available data on ICDs in patients with hyperprolactinemia as well as other disorders. Possible risk factors for the emergence of ICDs

Full Text available with Trip Pro

2018 European Journal of Endocrinology

11. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). (PubMed)

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). Prolactin elevations occur in people treated with antipsychotic medications and are often much higher in women than in men. Hyperprolactinemia is known to cause amenorrhea, oligomenorrhea, galactorrhea and gynecomastia in females and is also associated with sexual dysfunction (...) and bone loss. These side effects increase risk of antipsychotic nonadherence and suicide and pose significant problems in the long term management of women with schizophrenia. In this manuscript, we review the literature on prolactin; its physiology, plasma levels, side effects and strategies for treatment. We also present the rationale and protocol for an ongoing clinical trial to treat symptomatic hyperprolactinemia in premenopausal women with schizophrenia. More attention and focus are needed

Full Text available with Trip Pro

2013 BMC psychiatry

12. Idiopathic Hyperprolactinemia Presenting as Polycystic Ovary Syndrome in Identical Twin Sisters: A Case Report and Literature Review (PubMed)

the fact that androgen excess could be caused by either insulin resistance or hyperprolactinemia, we decided to treat one sister with insulin sensitizer metformin and other with dopamine agonist cabergoline. While cabergoline treatment resulted in normalization of prolactin levels and androgen excess, no significant biochemical or clinical improvement occurred with metformin treatment. Hyperprolactinemia was therefore considered to be the cause of androgen excess in both and cabergoline therapy (...) initiated in the other sister as well. Through the report, we conclude that diagnosis of PCOS should be made only after exclusion of alternative causes like hyperprolactinemia and detailed evaluation should be sought for any significant, unexplained prolactin elevation. Although rare, hyperprolactinemia can lead to androgen excess by increasing adrenal androgen secretion, which improves with dopamine agonist therapy.

Full Text available with Trip Pro

2018 Cureus

13. Dopamine Agonist in Hyperprolactinemia

Dopamine Agonist in Hyperprolactinemia Dopamine Agonist in Hyperprolactinemia Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Dopamine (...) Agonist in Hyperprolactinemia Dopamine Agonist in Hyperprolactinemia Aka: Dopamine Agonist in Hyperprolactinemia , Dopamine Agonist in Type 2 Diabetes Mellitus , Bromocriptine , Parlodel , Cabergoline , Dostinex , Bromocriptine QR , Cycloset From Related Chapters II. Indications III. Dosing: Hyperprolactinemia Bromocriptine (Parlodel) Larger safety database than Cabergoline (preferred in women trying to conceive) Start: 1.25 to 2.5 mg at bedtime Titrate: Increase by 2.5 mg every 3-7 days up to 15 mg

2015 FP Notebook

14. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. (PubMed)

Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. Hyperprolactinemia is an unwanted adverse effect present in several typical and atypical antipsychotics. Aripiprazole is a drug with partial agonist activity at the level of dopamine receptors D2, which may be effective for antipsychotic- induced hyperprolactinemia. Therefore, we analyzed the literature concerning the treatment of antipsychoticinduced (...) hyperprolactinemia with aripiprazole by updating a previous paper written on the same topic. More recent studies were reviewed. They showed that there are two options for the treatment of antipsychotic-induced hyperprolactinemia with aripiprazole. The safest strategy may require the addition of aripiprazole to ongoing treatments, in the case patients had previously responded to antipsychotic drugs and then developed hyperprolactinemia. However, it is advisable to monitor the patients in case relapses and/or side

2014 Recent patents on endocrine, metabolic & immune drug discovery

15. Paeoniflorin and liquiritin, two major constituents in Chinese herbal formulas used to treat hyperprolactinemia-associated disorders, inhibits prolactin secretion in prolactinoma cells by different mechanisms. (PubMed)

metoclopramide-induced hyperprolactinemia in rats. The contents of paeoniflorin and liquiritin in YRTJ Granule were 7.43 and 2.05mg/g extract, respectively. Paeoniflorin, liquiritin and bromocriptine (a dopamine D2 receptor (D2R) agonist) decreased prolactin concentration in MMQ cells expressing D2R. However, the effect of liquiritin and bromocriptine was abolished in GH3 cells lacking D2R expression. Interestingly, paeoniflorin still decreased prolactin concentration in GH3 cells in the same manner (...) Paeoniflorin and liquiritin, two major constituents in Chinese herbal formulas used to treat hyperprolactinemia-associated disorders, inhibits prolactin secretion in prolactinoma cells by different mechanisms. Paeoniflorin and liquiritin are major constituents in some Chinese herbal formulas, such as Yiru Tiaojing (YRTJ) Granule (a hospitalized preparation) and Peony-Glycyrrhiza Decoction, used for hyperprolactinemia-associated disorders.To investigate the effect of paeoniflorin and liquiritin

2017 Journal of Ethnopharmacology

16. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia. (PubMed)

Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia. Despite the widespread use of dopamine agonists for patients with prolactinomas and symptomatic idiopathic hyperprolactinemia for many decades, the optimal treatment strategy and duration of treatment is still not evident. This review highlights the effects of dopamine agonist withdrawal in patients with idiopathic hyperprolactinemia and prolactinomas in detail, including the factors influencing the success (...) of treatment outcome.It appeared that a subgroup of patients with a high likelihood of achieving remission could be identified on clinical criteria, which were incorporated in the Pituitary Society 2006 consensus guidelines. A recent systematic review and meta-analysis, however, demonstrated that the pooled proportion of patients with persisting normoprolactinemia after dopamine agonist withdrawal was only 21%, with a higher treatment success in idiopathic hyperprolactinemia (32%), compared with both

2011 Current opinion in endocrinology, diabetes, and obesity

17. Diagnosis and Treatment of Hyperprolactinemia

nonfunctioning pituitary macroadenomas, a prolactin level greater than 94 μg/liter reliably distinguished between prolactinomas and nonfunctioning adenomas ( ). Dopamine agonist therapy lowers prolactin levels and improves symptoms in patients with stalk compression, but it is not definitive therapy for a nonfunctioning adenoma. Fewer than 10% of patients with idiopathic hyperprolactinemia ultimately are found to harbor a microadenoma, and progression from a microadenoma to a macroadenoma is rare (...) hyperprolactinemia must evaluate the merits of their current medication program with their physicians. Assessment should include the availability of alternative medications—such as antipsychotic agents with lower dopamine antagonist potency ( , ) or aripiprazole, an atypical antipsychotic with both dopamine agonist and dopamine antagonist activity ( ) that can lower prolactin and reverse hyperprolactinemia-related side effects ( )—and their relative merits and downsides, and the potential adverse impact

Full Text available with Trip Pro

2011 The Endocrine Society

18. Administration of Kisspeptin in Patients With Hyperprolactinemia

: confirmed diagnosis of elevated levels of prolactin measured via blood test, no pituitary adenoma or a microprolactinoma (<10 mm). Patients with a macroprolactinoma confirmed on MRI imaging will be excluded, no history of a medication reaction requiring emergency medical care, no illicit drug use or excessive alcohol consumption (<10 drinks/week), not currently seeking fertility, breastfeeding or pregnant, no history of bilateral oophorectomy, willing to complete a dopamine agonist washout, normal (...) Administration of Kisspeptin in Patients With Hyperprolactinemia Administration of Kisspeptin in Patients With Hyperprolactinemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Administration of Kisspeptin

2016 Clinical Trials

19. Rheumatoid Arthritis, Kartagener's Syndrome, and Hyperprolactinemia: Who Started It? (PubMed)

of the immune system by recurrent infections. Furthermore, hyperprolactinemia has been hypothesized to mirror RA disease activity and case reports of treatment with dopamine agonists have led to the speculation of whether or not they represent a new line of experimental treatment in the future. Our patient was found to have both KS and hyperprolactinemia together in the setting of RA, and based on our literature search, this is the first reported case of such a combination. This strikes a very intriguing (...) Rheumatoid Arthritis, Kartagener's Syndrome, and Hyperprolactinemia: Who Started It? We report a case of an 18-year-old girl who presented to our hospital with history of recurrent respiratory infections, amenorrhea, and symmetric polyarthritis. She was diagnosed with rheumatoid arthritis (RA), Kartagener's syndrome (KS), and hyperprolactinemia. There have been very few case reports in the literature of RA occurring in the setting of KS, theoretically proposed to be due to chronic stimulation

Full Text available with Trip Pro

2016 Case reports in rheumatology

20. Management of antipsychotic-induced hyperprolactinemia (PubMed)

or augmentation) possessed the strongest evidence. Pharmacological treatments with less evidence encompassed dose reduction, switching to lower potency antipsychotics, and adding dopamine agonists. To date, no head-to-head studies have been published on the above approaches.Atypical antipsychotics with low affinity for dopamine (D2) receptors, such as olanzapine, are logical alternatives for the patient experiencing drug-induced hyperprolactinemia. When augmentation is clinically preferred to switching (...) , a viable option is the addition of a full or partial dopamine agonist, such as bromocriptine or aripiprazole, respectively. Patient-specific risk of psychiatric decompensation and the severity of symptomatic hyperprolactinemia should be weighed when formulating treatment strategies.

Full Text available with Trip Pro

2016 The Mental Health Clinician

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>